The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Polychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,042
Doxorubicin-Induced Cardiomyopathy
Singal, P. K., & Iliskovic, N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809243391307 · Cited by 1,845
American Joint Committee on Cancer (2010) · Springer eBooks · doi:10.1007/978-0-387-88441-7 · Cited by 1,328
Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211
AJCC Cancer Staging Manual, 6th edition
Schmoll, H.-J. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg077 · Cited by 729
Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M. K., Hoelzer, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1444 · Cited by 669
Research works printed but not linked: 5
- Chlebowski, 1989, Combination versus sequential single agent chemotherapy in advanced breast cancer: associations with metastatic sites and long-term survival. The Western Cancer Study Group and The Southeastern Cancer Study Group, Br J Cancer, 59, 227, 10.1038/bjc.1989.46 · doi:10.1038/bjc.1989.46
- Titgan, 1997, Prevention of palmar-plantar erythrodysesthesia associated with liposome-encapsulated doxorubicin (Doxil) by oral dexamethasone, Proc Am Soc Clin Oncol, 16, 288a
- Honecker, 2002, Reduction of skin toxicity of pegylated lipsomal doxorubicin (PLD) by concomitant administration of dexamethasone and pyridoxine (PYR) in patients (PTS) with anthracycline-sensitive malignancies: a phase I/II trial, J Cancer Res Clin Oncol, 128, 848
- Baas, 2000, Caelyx in malignant mesothelioma: a phase II EORTC study, Ann Oncol, 11, 697, 10.1023/A:1008346925273 · doi:10.1023/a:1008346925273
- Clin Oncol, 2000, Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment, J Clin Oncol, 18, 3115, 10.1200/JCO.2000.18.17.3115 · doi:10.1200/jco.2000.18.17.3115
Cited by
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Benson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
Liposomes as nanomedical devices
Bozzuto, G., & Molinari, A. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s68861 · Cited by 2,261
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Nanoparticle PEGylation for Imaging and Therapy
Jokerst, J. V., Lobovkina, T., Zare, R. N., & Gambhir, S. S. (2011) · Nanomedicine · doi:10.2217/nnm.11.19 · Cited by 2,046
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.654 · Cited by 1,795
Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies
Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,634
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Nanoparticle Delivery of Cancer Drugs
Wang, A. Z., Langer, R., & Farokhzad, O. C. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-040210-162544 · Cited by 1,561
Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems
Karimi, M., Ghasemi, A., Sahandi Zangabad, P., Rahighi, R., Moosavi Basri, S. M., Mirshekari, H., Amiri, M., Shafaei Pishabad, Z., Aslani, A., Bozorgomid, M., et al. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00798d · Cited by 1,519
Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance
Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., & Shao, A. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00193 · Cited by 1,451
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities
Cheng, Z., Al Zaki, A., Hui, J. Z., Muzykantov, V. R., & Tsourkas, A. (2012) · Science · doi:10.1126/science.1226338 · Cited by 1,322
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
Challenges in Development of Nanoparticle-Based Therapeutics
Desai, N. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9339-4 · Cited by 1,173
Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?
Nakamura, Y., Mochida, A., Choyke, P. L., & Kobayashi, H. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00437 · Cited by 1,101
Multistage nanoparticle delivery system for deep penetration into tumor tissue
Wong, C., Stylianopoulos, T., Cui, J., Martin, J., Chauhan, V. P., Jiang, W., Popović, Z., Jain, R. K., Bawendi, M. G., & Fukumura, D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018382108 · Cited by 1,062
Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization
Sun, Q., Zhou, Z., Qiu, N., & Shen, Y. (2017) · Advanced Materials · doi:10.1002/adma.201606628 · Cited by 1,058
Ernsting, M. J., Murakami, M., Roy, A., & Li, S.-D. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.013 · Cited by 1,012
Yusuf, A., Almotairy, A. R. Z., Henidi, H., Alshehri, O. Y., & Aldughaim, M. S. (2023) · Polymers · doi:10.3390/polym15071596 · Cited by 914
Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy
Yu, M. K., Park, J., & Jon, S. (2012) · Theranostics · doi:10.7150/thno.3463 · Cited by 883
Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Volkova, M., & Russell, R. (2012) · Current Cardiology Reviews · doi:10.2174/157340311799960645 · Cited by 872
Cardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management
Yeh, E. T. H., Tong, A. T., Lenihan, D. J., Yusuf, S. W., Swafford, J., Champion, C., Durand, J.-B., Gibbs, H., Zafarmand, A. A., & Ewer, M. S. (2004) · Circulation · doi:10.1161/01.cir.0000133187.74800.b9 · Cited by 843
Nichols, J. W., & Bae, Y. H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.057 · Cited by 834
Drug delivery by supramolecular design
Webber, M. J., & Langer, R. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00391a · Cited by 814
Yeh, M.-K., Chang, H.-I., & Cheng, M.-Y. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s26766 · Cited by 801
Nanoparticles for drug delivery in cancer treatment
Haley, B., & Frenkel, E. (2008) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.03.015 · Cited by 791
Clinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 772
Smith, L. A., Cornelius, V. R., Plummer, C. J., Levitt, G., Verrill, M., Canney, P., & Jones, A. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-337 · Cited by 753
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012070 · Cited by 744
Lipshultz, S. E., Adams, M. J., Colan, S. D., Constine, L. S., Herman, E. H., Hsu, D. T., Hudson, M. M., Kremer, L. C., Landy, D. C., Miller, T. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e3182a88099 · Cited by 612
Emerging use of nanoparticles in diagnosis and treatment of breast cancer
Yezhelyev, M. V., Gao, X., Xing, Y., Al-Hajj, A., Nie, S., & O'Regan, R. M. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70793-8 · Cited by 577
Cancer treatment therapies: traditional to modern approaches to combat cancers
Kaur, R., Bhardwaj, A., & Gupta, S. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08809-3 · Cited by 561
Molecular Imaging with Theranostic Nanoparticles
Jokerst, J. V., & Gambhir, S. S. (2011) · Accounts of Chemical Research · doi:10.1021/ar200106e · Cited by 548
Improving drug delivery to solid tumors: Priming the tumor microenvironment
Khawar, I. A., Kim, J. H., & Kuh, H.-J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.018 · Cited by 533
Dawidczyk, C. M., Kim, C., Park, J. H., Russell, L. M., Lee, K. H., Pomper, M. G., & Searson, P. C. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.036 · Cited by 527
Nanotheranostics for personalized medicine
Mura, S., & Couvreur, P. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.06.006 · Cited by 527
Combining two strategies to improve perfusion and drug delivery in solid tumors
Stylianopoulos, T., & Jain, R. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318415110 · Cited by 508
The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors
Izci, M., Maksoudian, C., Manshian, B. B., & Soenen, S. J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00779 · Cited by 506
Kievit, F. M., & Zhang, M. (2011) · Advanced Materials · doi:10.1002/adma.201102313 · Cited by 496
Nonporous silica nanoparticles for nanomedicine application
Tang, L., & Cheng, J. (2013) · Nano Today · doi:10.1016/j.nantod.2013.04.007 · Cited by 488
Photoswitchable Nanoparticles for Triggered Tissue Penetration and Drug Delivery
Tong, R., Hemmati, H. D., Langer, R., & Kohane, D. S. (2012) · Journal of the American Chemical Society · doi:10.1021/ja211888a · Cited by 477
Cancer drugs and the heart: importance and management
Suter, T. M., & Ewer, M. S. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs181 · Cited by 472
Wouters, K. A., Kremer, L. C. M., Miller, T. L., Herman, E. H., & Lipshultz, S. E. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05759.x · Cited by 453
Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors
Laginha, K. M., Verwoert, S., Charrois, G. J. R., & Allen, T. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0343 · Cited by 441
Chemophototherapy: An Emerging Treatment Option for Solid Tumors
Luo, D., Carter, K. A., Miranda, D., & Lovell, J. F. (2017) · Advanced Science · doi:10.1002/advs.201600106 · Cited by 436
Liang, C., Xu, L., Song, G., & Liu, Z. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00458j · Cited by 435
Microfluidic formulation of nanoparticles for biomedical applications
Shepherd, S. J., Issadore, D., & Mitchell, M. J. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120826 · Cited by 433
Cancer Nanotechnology: A New Revolution for Cancer Diagnosis and Therapy
Chaturvedi, V. K., Singh, A., Singh, V. K., & Singh, M. P. (2019) · Current Drug Metabolism · doi:10.2174/1389200219666180918111528 · Cited by 418
Aghebati‐Maleki, A., Dolati, S., Ahmadi, M., Baghbanzhadeh, A., Asadi, M., Fotouhi, A., Yousefi, M., & Aghebati‐Maleki, L. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29126 · Cited by 417
Bhatia, S. N., Chen, X., Dobrovolskaia, M. A., & Lammers, T. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00496-9 · Cited by 406
Cardiovascular Complications of Cancer Therapy
Chang, H.-M., Moudgil, R., Scarabelli, T., Okwuosa, T. M., & Yeh, E. T. H. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.1096 · Cited by 385
Overchuk, M., & Zheng, G. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.024 · Cited by 383
Bridging Bio–Nano Science and Cancer Nanomedicine
Björnmalm, M., Thurecht, K. J., Michael, M., Scott, A. M., & Caruso, F. (2017) · ACS Nano · doi:10.1021/acsnano.7b04855 · Cited by 382
PEGylation in anti-cancer therapy: An overview
Mishra, P., Nayak, B., & Dey, R. K. (2016) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2015.08.011 · Cited by 382
Nanoparticle Characterization: State of the Art, Challenges, and Emerging Technologies
Cho, E. J., Holback, H., Liu, K. C., Abouelmagd, S. A., Park, J., & Yeo, Y. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300697h · Cited by 382
Mamot, C., Drummond, D. C., Noble, C. O., Kallab, V., Guo, Z., Hong, K., Kirpotin, D. B., & Park, J. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1093 · Cited by 382
Nanomedicine of synergistic drug combinations for cancer therapy – Strategies and perspectives
Zhang, R. X., Wong, H. L., Xue, H. Y., Eoh, J. Y., & Wu, X. Y. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.012 · Cited by 380
Odyssey of a cancer nanoparticle: From injection site to site of action
Nichols, J. W., & Bae, Y. H. (2012) · Nano Today · doi:10.1016/j.nantod.2012.10.010 · Cited by 364
Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies
Nounou, M. I., ElAmrawy, F., Ahmed, N., Abdelraouf, K., Goda, S., & Syed-Sha-Qhattal, H. (2015) · Breast Cancer: Basic and Clinical Research · doi:10.4137/bcbcr.s29420 · Cited by 364
Nanovehicular Intracellular Delivery Systems
Prokop, A., & Davidson, J. M. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21270 · Cited by 363
Doxorubicin: nanotechnological overviews from bench to bedside
Cagel, M., Grotz, E., Bernabeu, E., Moretton, M. A., & Chiappetta, D. A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.005 · Cited by 362
Liposomal encapsulated anti-cancer drugs
Hofheinz, R.-D., Gnad-Vogt, S. U., Beyer, U., & Hochhaus, A. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000167902.53039.5a · Cited by 355
Tada, H., Higuchi, H., Wanatabe, T. M., & Ohuchi, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1185 · Cited by 352
Wenningmann, N., Knapp, M., Ande, A., Vaidya, T. R., & Ait-Oudhia, S. (2019) · Molecular Pharmacology · doi:10.1124/mol.119.115725 · Cited by 334
Advanced drug delivery to the lymphatic system: lipid-based nanoformulations
Darwis, Y., Ali Khan, A., Mudassir, J., & Mohtar, N. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s41521 · Cited by 333
Štěrba, M., Popelová, O., Vávrová, A., Jirkovský, E., Kovaříková, P., Geršl, V., & Šimůnek, T. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4795 · Cited by 329
Improvement of drug safety by the use of lipid-based nanocarriers
Lim, S. B., Banerjee, A., & Önyüksel, H. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.06.002 · Cited by 324
Shafei, A., El-Bakly, W., Sobhy, A., Wagdy, O., Reda, A., Aboelenin, O., Marzouk, A., El Habak, K., Mostafa, R., Ali, M. A., et al. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.09.059 · Cited by 318
Passive versus Active Tumor Targeting Using RGD- and NGR-Modified Polymeric Nanomedicines
Kunjachan, S., Pola, R., Gremse, F., Theek, B., Ehling, J., Moeckel, D., Hermanns-Sachweh, B., Pechar, M., Ulbrich, K., Hennink, W. E., et al. (2014) · Nano Letters · doi:10.1021/nl404391r · Cited by 317
Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management
Barry, E., Alvarez, J. A., Scully, R. E., Miller, T. L., & Lipshultz, S. E. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.8.1039 · Cited by 307
PANoptosis: Mechanisms, biology, and role in disease
Sun, X., Yang, Y., Meng, X., Li, J., Liu, X., & Liu, H. (2024) · Immunological Reviews · doi:10.1111/imr.13279 · Cited by 305
Artificial exosomes for translational nanomedicine
Li, Y.-J., Wu, J.-Y., Liu, J., Xu, W., Qiu, X., Huang, S., Hu, X.-B., & Xiang, D.-X. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00986-2 · Cited by 303
Rafiyath, S. M., Rasul, M., Lee, B., Wei, G., Lamba, G., & Liu, D. (2012) · Experimental Hematology & Oncology · doi:10.1186/2162-3619-1-10 · Cited by 302
Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming
Mattioli, R., Ilari, A., Colotti, B., Mosca, L., Fazi, F., & Colotti, G. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101205 · Cited by 294
Zhou, H., Fan, Z., Deng, J., Lemons, P. K., Arhontoulis, D. C., Bowne, W. B., & Cheng, H. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b00820 · Cited by 293
Supramolecular Nanodevices: From Design Validation to Theranostic Nanomedicine
Cabral, H., Nishiyama, N., & Kataoka, K. (2011) · Accounts of Chemical Research · doi:10.1021/ar200094a · Cited by 292
Petersen, G. H., Alzghari, S. K., Chee, W., Sankari, S. S., & La-Beck, N. M. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.04.028 · Cited by 290
Ishida, T., Atobe, K., Wang, X., & Kiwada, H. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.08.017 · Cited by 287
Perspectives on the past, present, and future of cancer nanomedicine
Youn, Y. S., & Bae, Y. H. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.05.008 · Cited by 285
Nanoparticle–blood interactions: the implications on solid tumour targeting
Lazarovits, J., Chen, Y. Y., Sykes, E. A., & Chan, W. C. W. (2015) · Chemical Communications · doi:10.1039/c4cc07644c · Cited by 285
Design considerations for nanotherapeutics in oncology
Stylianopoulos, T., & Jain, R. K. (2015) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.07.015 · Cited by 280
Kuerban, K., Gao, X., Zhang, H., Liu, J., Dong, M., Wu, L., Ye, R., Feng, M., & Ye, L. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.02.002 · Cited by 277
Pearce, A. K., & O’Reilly, R. K. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00456 · Cited by 275
Gaillard, P. J., Appeldoorn, C. C. M., Dorland, R., van Kregten, J., Manca, F., Vugts, D. J., Windhorst, B., van Dongen, G. A. M. S., de Vries, H. E., Maussang, D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0082331 · Cited by 273
Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
Egusquiaguirre, S. P., Igartua, M., Hernández, R. M., & Pedraz, J. L. (2012) · Clinical and Translational Oncology · doi:10.1007/s12094-012-0766-6 · Cited by 268
Werner, M. E., Cummings, N. D., Sethi, M., Wang, E. C., Sukumar, R., Moore, D. T., & Wang, A. Z. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.02.009 · Cited by 267
Ali, E. S., Sharker, S. M., Islam, M. T., Khan, I. N., Shaw, S., Rahman, M. A., Uddin, S. J., Shill, M. C., Rehman, S., Das, N., et al. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.011 · Cited by 267
Ranjan, A., Jacobs, G. C., Woods, D. L., Negussie, A. H., Partanen, A., Yarmolenko, P. S., Gacchina, C. E., Sharma, K. V., Frenkel, V., Wood, B. J., et al. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.011 · Cited by 267
Different anthracycline derivates for reducing cardiotoxicity in cancer patients
van Dalen, E. C., Michiels, E. M. C., Caron, H. N., & Kremer, L. C. M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005006.pub4 · Cited by 265
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (‘hand-foot’ syndrome)
Lorusso, D., Di Stefano, A., Carone, V., Fagotti, A., Pisconti, S., & Scambia, G. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl477 · Cited by 265
Third consensus on medical treatment of metastatic breast cancer
Beslija, S., Bonneterre, J., Burstein, H. J., Cocquyt, V., Gnant, M., Heinemann, V., Jassem, J., Köstler, W. J., Krainer, M., Menard, S., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp261 · Cited by 263
What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right
Sun, D., Zhou, S., & Gao, W. (2020) · ACS Nano · doi:10.1021/acsnano.9b09713 · Cited by 263
Challenges in design of translational nanocarriers
Sun, Q., Radosz, M., & Shen, Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.042 · Cited by 261
Leonard, R. C. F., Williams, S., Tulpule, A., Levine, A. M., & Oliveros, S. (2009) · The Breast · doi:10.1016/j.breast.2009.05.004 · Cited by 257
Cancer‐Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery
Vaughan, H. J., Green, J. J., & Tzeng, S. Y. (2020) · Advanced Materials · doi:10.1002/adma.201901081 · Cited by 255
Nanoparticle-Based Delivery Systems for Vaccines
Bezbaruah, R., Chavda, V. P., Nongrang, L., Alom, S., Deka, K., Kalita, T., Ali, F., Bhattacharjee, B., & Vora, L. (2022) · Vaccines · doi:10.3390/vaccines10111946 · Cited by 253
Metadata
- Authors
- O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., Orlandi, F., Mellars, L., Alland, L., & Tendler, C.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2004-03
- Volume
- 15
- Issue
- 3
- Pages
- 440-449
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2096593771
- Cited by
- 1,738
- References
- 23
- FWCI
- 28.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 5790 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.